U.S. markets closed
  • S&P 500

    4,448.98
    +53.34 (+1.21%)
     
  • Dow 30

    34,764.82
    +506.50 (+1.48%)
     
  • Nasdaq

    15,052.24
    +155.40 (+1.04%)
     
  • Russell 2000

    2,259.04
    +40.48 (+1.82%)
     
  • Crude Oil

    73.24
    +1.01 (+1.40%)
     
  • Gold

    1,742.80
    -36.00 (-2.02%)
     
  • Silver

    22.52
    -0.39 (-1.69%)
     
  • EUR/USD

    1.1744
    +0.0048 (+0.41%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • GBP/USD

    1.3724
    +0.0104 (+0.76%)
     
  • USD/JPY

    110.3000
    +0.5220 (+0.48%)
     
  • BTC-USD

    44,724.62
    +1,221.91 (+2.81%)
     
  • CMC Crypto 200

    1,119.18
    +10.26 (+0.92%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Cowen Initiates Coverage On Molecular Partners With Price Target Of $50

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of , implying an upside potential of more than 150%.

  • The company and its partner Novartis AG (NYSE: NVS) recently shared preclinical data showing that ensovibep retains full potency and viral inhibition against all known COVID-19 variants in circulation, including the key Delta variants.

  • It outlined progress on its global Phase 2/3 study in ambulatory COVID-19 patients.

  • Interim data from EMPATHY Phase 2/3 trial is expected in H2 2021, and complete topline data expected in early 2022.

  • The company started trading in the U.S market just a month back, wherein it sold 3 million shares at $21.25 each.

  • The stock is already trading on the Swiss exchange since 2014.

  • Price Action: MOLN shares are up 3.3% at $19.88 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.